Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phio Pharmaceuticals (PHIO) EBITDA Margin (2016 - 2019)

Historic EBITDA Margin for Phio Pharmaceuticals (PHIO) over the last 8 years, with Q1 2019 value amounting to 10219.05%.

  • Phio Pharmaceuticals' EBITDA Margin fell 4842700.0% to 10219.05% in Q1 2019 from the same period last year, while for Dec 2019 it was 42795.24%, marking a year-over-year decrease of 374590100.0%. This contributed to the annual value of 42795.24% for FY2019, which is 374590100.0% down from last year.
  • Latest data reveals that Phio Pharmaceuticals reported EBITDA Margin of 10219.05% as of Q1 2019, which was down 4842700.0% from 2617.54% recorded in Q3 2018.
  • Phio Pharmaceuticals' EBITDA Margin's 5-year high stood at 2617.54% during Q3 2018, with a 5-year trough of 24611.11% in Q2 2016.
  • Over the past 5 years, Phio Pharmaceuticals' median EBITDA Margin value was 9976.92% (recorded in 2018), while the average stood at 11855.58%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by -137852900bps in 2016, then plummeted by -4842700bps in 2019.
  • Quarter analysis of 5 years shows Phio Pharmaceuticals' EBITDA Margin stood at 8664.71% in 2015, then plummeted by -184bps to 24611.11% in 2016, then surged by 46bps to 13273.33% in 2017, then skyrocketed by 80bps to 2617.54% in 2018, then crashed by -290bps to 10219.05% in 2019.
  • Its last three reported values are 10219.05% in Q1 2019, 2617.54% for Q3 2018, and 3274.14% during Q2 2018.